JPMorgan Resumes Pfizer (PFE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Jefferies Reiterates Buy on Pfizer (PFE) Post Allergen Collapse, PT Trimmed to $39
April 7, 2016 8:23 AM EDTJefferies analyst, Jeffrey Holford, performed a SOTP valuation on fizer (NYSE: PFE) after the Allergan deal was terminated and believes shares have 18% upside by 2017 as the decision on the split has been reinstated to 2016. He also sees the potential for major M&A to give more critical mass to GIP in particular. Using a SOTP analysis, he derives a value of... More
Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)
April 6, 2016 6:45 AM EDTPfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change... More
